삼광의료재단
서울특별시 서초구 바우뫼로41길 58 (양재동, 선화빌딩)
검사기관 11365200
Tel. 1661-5117
www.smlab.co.kr

Report Date: 22 Oct 2025   1 of 18

SML Samkwang Medical Lab

Patient Name: 강관식	**Primary Tumor Site:** Urinary bladder
Gender: M	**Collection Date:** 2022.10.31.
Sample ID: N25-253	

Sample Cancer Type: Bladder Cancer

Report Highlights

3 Relevant Biomarkers
0 Therapies Available
1 Clinical Trials

Relevant Bladder Cancer Findings

Gene	Finding	Gene	Finding
BRAF	None detected	NTRK1	None detected
ERBB2	None detected	NTRK2	None detected
FGFR2	None detected	NTRK3	None detected
FGFR3	None detected	RET	None detected

Genomic Alteration	Finding
Tumor Mutational Burden	**8.55 Mut/Mb measured**

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IIC	*ATRX deletion* ATRX, chromatin remodeler Locus: chrX:76763769	None*	None*	1
IIC	*BARD1 deletion* BRCA1 associated RING domain 1 Locus: chr2:215593375	None*	None*	1
IIC	*CHEK2 deletion* checkpoint kinase 2 Locus: chr22:29083868	None*	None*	1

* **Public data sources included in relevant therapies: FDA**1, NCCN, **EMA**2, ESMO
* **Public data sources included in prognostic and diagnostic significance:** NCCN, ESMO
Line of therapy: I: First-line therapy, II+: Other line of therapy
Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Prevalent cancer biomarkers without relevant evidence based on included data sources

CUL4B deletion, KMT2A p.(S3506) c.10517C>G, Microsatellite stable, RNASEH2B deletion, TP53 p.(E285K) c.853G>A, TERT c.-57A>C, ZRSR2 deletion, BCOR deletion, USP9X deletion, DDX3X deletion, KDM6A deletion, RBM10 deletion, KDM5C deletion, SMC1A deletion, AMER1 deletion, ZMYM3 deletion, STAG2 deletion, PHF6 deletion, Tumor Mutational Burden*

Variant Details

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect
KMT2A	p.(S3506*)	c.10517C>G	.	chr11:118377124	21.82%	NM_001197104.2	nonsense
TP53	p.(E285K)	c.853G>A	COSM10722	chr17:7577085	26.07%	NM_000546.6	missense
TERT	p.(?)	c.-57A>C	COSM1307007	chr5:1295161	21.59%	NM_198253.3	unknown
RHOA	p.(I46T)	c.137T>C	.	chr3:49412886	20.85%	NM_001664.4	missense
GHR	p.(E553Q)	c.1657G>C	.	chr5:42719266	18.60%	NM_000163.5	missense
HDAC9	p.(L867V)	c.2599C>G	.	chr7:18875535	43.46%	NM_178425.3	missense
POLE	p.(E967Q)	c.2899G>C	.	chr12:133237716	23.66%	NM_006231.4	missense
AKT1	p.(H468Q)	c.1404C>G	.	chr14:105236717	46.90%	NM_001014431.2	missense
ZFHX3	p.(S202L)	c.605C>T	.	chr16:72993440	31.26%	NM_006885.4	missense
BRCA1	p.(S1514C)	c.4541C>G	.	chr17:41226482	21.64%	NM_007294.4	missense

Copy Number Variations

Gene	Locus	Copy Number	CNV Ratio
ATRX	chrX:76763769	0.14	0.6
BARD1	chr2:215593375	1	0.8
CHEK2	chr22:29083868	1	0.68
CUL4B	chrX:119660593	0.16	0.6
RNASEH2B	chr13:51484145	0.6	0.7
ZRSR2	chrX:15808582	0.37	0.65
BCOR	chrX:39911340	0.09	0.59
USP9X	chrX:40982869	0.07	0.58
DDX3X	chrX:41193501	0	0.56
KDM6A	chrX:44732715	0.3	0.64
RBM10	chrX:47006798	0.26	0.62
KDM5C	chrX:53221892	0.16	0.6
SMC1A	chrX:53406966	0.02	0.57
AMER1	chrX:63409727	0.05	0.58
ZMYM3	chrX:70460753	0.09	0.59
STAG2	chrX:123156472	0	0.57
PHF6	chrX:133511628	0.19	0.61
EIF1AX	chrX:20148599	0.14	0.6
ARAF	chrX:47422311	0	0.56
AR	chrX:66766015	0	0.5

Biomarker Descriptions

ATRX deletion

ATRX, chromatin remodeler

Background: The ATRX gene encodes the ATRX chromatin remodeler and ATPase/helicase domain protein, which belongs to SWI/SNF family of chromatin remodeling proteins[1]. The SWI/SNF proteins are a group of DNA translocases that use ATP hydrolysis to remodel chromatin structure and maintain genomic integrity by controlling transcriptional regulation, DNA repair, and chromosome stability through the regulation of telomere length[34,35,36,37]. ATRX is a tumor suppressor that interacts with the MRE11-RAD50-NBN (MRN) complex, which is involved in double-stranded DNA (dsDNA) break repair[38,39,40].

Alterations and prevalence: Somatic mutations of ATRX are observed in 38% of brain lower grade glioma, 15% of uterine corpus endometrial carcinoma, 14% of sarcoma, 9% of glioblastoma multiforme and skin cutaneous melanoma, 7% of colorectal adenocarcinoma, 6% of lung adenocarcinoma, stomach adenocarcinoma, and cervical squamous cell carcinoma, 5% of bladder urothelial carcinoma and lung squamous cell carcinoma, 4% of adrenocortical carcinoma, head and neck squamous cell carcinoma and uterine carcinosarcoma, and 2% of diffuse large B-cell lymphoma, ovarian serous cystadenocarcinoma, breast invasive carcinoma, pheochromocytoma and paraganglioma, kidney renal clear cell carcinoma, pancreatic adenocarcinoma, liver hepatocellular carcinoma and kidney chromophobe[5,6]. Biallelic deletion of ATRX is observed in 7% of sarcoma, 3% of kidney chromophobe, and 2% of brain lower grade glioma[5,6]. Although alterations of ATRX in pediatric populations are rare, somatic mutations are observed in 6% of gliomas, 4% of bone cancer, 3% of soft tissue sarcoma, and less than 1% of B-lymphoblastic leukemia/lymphoma (2 in 252 cases), embryonal tumor (3 in 332 cases), and leukemia (2 in 354 cases)[6]. Biallelic deletion of ATRX is observed in 1% of peripheral nervous system tumors (1 in 91 cases) in and less than 1% of B-lymphoblastic leukemia/lymphoma (2 in 731 cases)[6].

Potential relevance: Currently, no therapies are approved for ATRX aberrations. Loss of ATRX protein expression correlates with the presence of ATRX mutations[41,42]. ATRX deficiency along with IDH mutation and TP53 mutation is diagnostic of astrocytoma IDH-mutant as defined by the World Health Organization (WHO)[43,44].

BARD1 deletion

BRCA1 associated RING domain 1

Background: The BARD1 gene encodes the BRCA1 associated RING domain 1 protein which binds to BRCA1 and contributes to the in vitro E3 ligase activity that is required for the tumor suppressor function of the BRCA1 gene[1,120]. The cysteine-rich N-terminal RING finger domains of BARD1 and BRCA1 heterodimerize to regulate a diverse range of cellular pathways, such as ubiquitination, transcriptional regulation, and homologous recombination repair (HRR) of double-stranded DNA damage[1,120,121,122]. Mutual stability between BARD1 and BRCA1 is essential in maintaining HRR functionality. Genetic alterations in either BARD1 or BRCA1 can disrupt the BARD1/BRCA1 interaction[1,121,123,124]. BARD1 is a tumor suppressor and loss of function (LOF) mutations are implicated in the BRCAness phenotype, which is characterized by a defect in HRR mimicking BRCA1 or BRCA2 loss[124,125]. Copy number deletion, nonsense or frameshift mutations attributed to BARD1 LOF and are associated with familial breast cancer susceptibility[123]. Independent of BRCA1, BARD1 acts as a mediator of apoptosis by binding to p53[126]. Specifically, the BARD1 Q564H germline mutation is associated with a decrease in pro-apoptotic activity and implicated in cases of breast and endometrial cancer[126,127].

Alterations and prevalence: Somatic mutations in BARD1 are found in 5% of uterine cancer, 3% of stomach cancer as well as melanoma, and 2% of bladder cancer as well as lung adenocarcinoma[5,6]. BARD1 copy number loss is observed in 2% of mesothelioma, head and neck cancer, and esophageal cancer[5,6].

Potential relevance: The PARP inhibitor, olaparib[128] is approved (2020) for metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious, germline or somatic mutations in HRR genes that includes BARD1. In 2022, the FDA granted fast track designation to the small molecule inhibitor, pidnarulex[129], for BRCA1/2, PALB2, or other homologous recombination deficiency (HRD) mutations in breast and ovarian cancers.

CHEK2 deletion

checkpoint kinase 2

Background: The CHEK2 gene encodes the checkpoint kinase-2 serine/threonine kinase, which is a cell-cycle checkpoint regulator. In response to DNA damage, CHEK2 is phosphorylated by ATM and subsequently phosphorylates and negatively regulates CDC25C to prevent entry into mitosis[164]. CHEK2 also stabilizes p53, leading to cell-cycle arrest in G1 phase, and is capable of phosphorylating BRCA1 and promoting DNA repair including homologous recombination repair (HRR)[165,166,167]. Germline mutations in the CHEK2 gene are associated with Li-Fraumeni syndrome and inherited risk of breast cancer[168,169,170].

Biomarker Descriptions (continued)

Alterations and prevalence: Consistent with its role as a tumor suppressor, CHEK2 is enriched for deleterious truncating mutations. Somatic mutations in CHEK2 are common (2-6%) in uterine carcinoma, bladder carcinoma, and lung adenocarcinoma[5,6]. CHEK2 gene deletions are observed in adrenocortical carcinoma, thymoma, and prostate cancer[5,6].

Potential relevance: The PARP inhibitor, olaparib[128] is approved (2020) for metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious, germline or somatic mutations in HRR genes that includes CHEK2. Additionally, talazoparib[171] in combination with enzalutamide is approved (2023) for mCRPC with mutations in HRR genes that includes CHEK2. In 2022, the FDA granted fast track designation to the small molecule inhibitor, pidnarulex[129], for BRCA1/2, PALB2, or other homologous recombination deficiency (HRD) mutations in breast and ovarian cancers.

CUL4B deletion

cullin 4B

Background: The CUL4B gene encodes cullin 4B, a member of the cullin family, which includes CUL1, CUL2, CUL3, CUL4a, CUL5, CUL7, and Parc[1,2]. CUL4B belongs to the CUL4 subfamily which also includes CUL4A[3]. CUL4A and CUL4B share greater than 80% sequence identity and functional redundancy[3,4]. Cullin proteins share a conserved cullin homology domain and act as molecular scaffolds for RING E3 ubiquitin ligases to assemble into cullin-RING ligase complexes (CRLs)[2]. CUL4B is part of the CRL4 complex which is responsible for ubiquitination and degradation of a variety of substrates where substrate specificity is dependent on the substrate recognition component of the CRL4 complex[4]. CRL4 substrates include oncoproteins, tumor suppressors, nucleotide excision repair proteins, cell cycle promoters, histone methylation proteins, and tumor-related signaling molecules, thereby impacting various processes critical to tumor development and progression and supporting a complex role of CUL4B in oncogenesis[3,4].

Alterations and prevalence: Somatic mutations in CUL4B are observed in 9% of uterine corpus endometrial carcinoma, 5% of skin cutaneous melanoma, and 2% of bladder urothelial carcinoma, cervical squamous cell carcinoma, colorectal adenocarcinoma, uterine carcinosarcoma, brain lower grade glioma, and lung squamous cell carcinoma[5,6]. Amplification of CUL4B is observed in 2% of diffuse large B-cell lymphoma[5,6]. Biallelic loss of CUL4B is observed in 1% sarcoma and testicular germ cell tumors[5,6].

Potential relevance: Currently, no therapies are approved for CUL4B aberrations.

KMT2A p.(S3506*) c.10517C>G

lysine methyltransferase 2A

Background: The KMT2A gene encodes lysine methyltransferase 2A, a transcriptional coactivator and histone H3 lysine 4 (H3K4) methyltransferase[1,70]. KMT2A, also known as mixed lineage leukemia (MLL), is part of the SET domain protein methyltransferase superfamily[70]. KMT2A influences the epigenetic regulation of several cellular functions, including neurogenesis, hematopoiesis, and osteogenesis[71]. Located at the chromosomal position 11q23, KMT2A is the target of recurrent chromosomal rearrangements observed in several leukemia subtypes, including MLL, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL)[72]. These translocations encode KMT2A fusion proteins that are oncogenic with simultaneous loss of KMT2A H3K4 methyltransferase activity[72]. Loss of methyltransferase activity, along with gain-of-function partner gene activation, contributes to increased HOX gene expression and promotes the transformation of hematopoietic cells into leukemic stem cells[72,73,74,75].

Alterations and prevalence: KMT2A fusions are observed in 3-10% of adult AML cases with the highest frequencies in therapy-related AML (9%) and patients younger than 60 years (5%)[5,6,72,76]. KMT2A rearrangements including t(4;11)(q21;q23)/AFF1::KMT2A, t(9;11)(p22;q23)/MLLT3::KMT2A, t(11;19)(q23;p13.3)/KMT2A::MLLT1, t(10;11)(p12;q23)/MLLT10::KMT2A, and t(6;11)(q27;q23)/AFDN::KMT2A translocations account for about 80% of all KMT2A rearranged leukemias[72]. KMT2A alterations observed in solid tumors include nonsense or frameshift mutations, which result in KMT2A truncation and loss of methyltransferase activity[5,77]. KMT2A alterations are also observed in pediatric cancers[5,6]. In infant acute leukemic cases, KMT2A rearrangement is reported in more than 70% of pediatric patients diagnosed with either AML or ALL and is observed in 5% of T-lymphoblastic leukemia/lymphoma[5,6,72,78,79].

Potential relevance: KMT2A fusions are associated with variable prognosis based on the partner genes involved in the fusion[22,23]. For example, t(6;11)(q27;q23)/AFDN::KMT2A fusions are associated with poor prognosis, whereas t(9;11)(p22;q23)/MLLT3::KMT2A fusions confer a more favorable or intermediate prognosis in AML[80,81,82]. Additionally, 11q23 rearrangements define an unfavorable karyotype in patients diagnosed with primary myelofibrosis (PMF) and may confer intermediate to high risk depending on concurrent cytogenetic abnormalities[83]. KMT2A fusion is also associated with poor risk in adult and pediatric ALL[84,85,86]. Translocations in KMT2A are recognized by the World Health Organization (WHO) as a molecular subtype of B-lymphoblastic leukemia/lymphoma with KMT2A-rearrangement[87]. In 2024, the FDA approved the oral menin inhibitor, revumenib[88], for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia harboring a KMT2A rearrangement. In 2024, the FDA also granted fast track designation to the small molecule inhibitor, DSP-5336, for the treatment of patients with relapsed or refractory AML with KMT2A rearrangements[89].

Biomarker Descriptions (continued)

Microsatellite stable

Background: Microsatellites are short tandem repeats (STR) of 1 to 6 bases of DNA between 5 to 50 repeat units in length. There are approximately 0.5 million STRs that occupy 3% of the human genome[142]. Microsatellite instability (MSI) is defined as a change in the length of a microsatellite in a tumor as compared to normal tissue[143,144]. MSI is closely tied to the status of the mismatch repair (MMR) genes. In humans, the core MMR genes include MLH1, MSH2, MSH6, and PMS2[145]. Mutations and loss of expression in MMR genes, known as defective MMR (dMMR), lead to MSI. In contrast, when MMR genes lack alterations, they are referred to as MMR proficient (pMMR). Consensus criteria were first described in 1998 and defined MSI-high (MSI-H) as instability in two or more of the following five markers: BAT25, BAT26, D5S346, D2S123, and D17S250[146]. Tumors with instability in one of the five markers were defined as MSI-low (MSI-L) whereas, those with instability in zero markers were defined as MS-stable (MSS)[146]. Tumors classified as MSI-L are often phenotypically indistinguishable from MSS tumors and tend to be grouped with MSS[147,148,149,150,151]. MSI-H is a hallmark of Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, which is caused by germline mutations in the MMR genes[144]. LS is associated with an increased risk of developing colorectal cancer, as well as other cancers, including endometrial and stomach cancer[143,144,148,152].

Alterations and prevalence: The MSI-H phenotype is observed in 30% of uterine corpus endothelial carcinoma, 20% of stomach adenocarcinoma, 15-20% of colon adenocarcinoma, and 5-10% of rectal adenocarcinoma[143,144,153,154]. MSI-H is also observed in 5% of adrenal cortical carcinoma and at lower frequencies in other cancers such as esophageal, liver, and ovarian cancers[153,154].

Potential relevance: Anti-PD-1 immune checkpoint inhibitors including pembrolizumab[155] (2014) and nivolumab[156] (2015) are approved for patients with MSI-H or dMMR colorectal cancer who have progressed following chemotherapy. Pembrolizumab[155] is also approved as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR with disease progression on prior therapy who are not candidates for surgery or radiation. Importantly, pembrolizumab is approved for the treatment of MSI-H or dMMR solid tumors that have progressed following treatment, with no alternative option and is the first anti-PD-1 inhibitor to be approved with a tumor agnostic indication[155]. Dostarlimab[157] (2021) is also approved for dMMR recurrent or advanced endometrial carcinoma or solid tumors that have progressed on prior treatment and is recommended as a subsequent therapy option in dMMR/ MSI-H advanced or metastatic colon or rectal cancer[149,158]. The cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody, ipilimumab[159] (2011), is approved alone or in combination with nivolumab in MSI-H or dMMR colorectal cancer that has progressed following treatment with chemotherapy. MSI-H may confer a favorable prognosis in colorectal cancer although outcomes vary depending on stage and tumor location[149,160,161]. Specifically, MSI-H is a strong prognostic indicator of better overall survival (OS) and relapse free survival (RFS) in stage II as compared to stage III colorectal cancer patients[161]. The majority of patients with tumors classified as either MSS or pMMR do not benefit from treatment with single-agent immune checkpoint inhibitors as compared to those with MSI-H tumors[162,163]. However, checkpoint blockade with the addition of chemotherapy or targeted therapies have demonstrated response in MSS or pMMR cancers[162,163].

RNASEH2B deletion

ribonuclease H2 subunit B

Background: The RNASEH2B gene encodes the ribonuclease H2 subunit B protein[1]. RNASEH2B functions as an auxiliary subunit of RNase H2 holoenzyme along with RNASEH2C and the catalytic subunit RNASEH2A[53,54]. RNase H2 is responsible for the removal of ribonucleotides that have been misincorporated in DNA, and also degrades DNA:RNA hybrids formed during transcription[53]. Specifically, RNase H2 is observed to interact with BRCA1 for DNA:RNA hybrid resolution at double-strand breaks (DSBs) through homologous recombination repair (HRR)[53].

Alterations and prevalence: Somatic mutations in RNASEH2B are observed in 3% of uterine corpus endometrial carcinoma, and 2% of skin cutaneous melanoma[5,6]. RNASEH2B biallelic deletions are observed in 10% of prostate adenocarcinoma, 7% sarcoma, 6% of bladder urothelial carcinoma, and 3% of ovarian serous cystadenocarcinoma[5,6].

Potential relevance: Currently, no therapies are approved for RNASEH2B aberrations.

TP53 p.(E285K) c.853G>A

tumor protein p53

Background: The TP53 gene encodes the tumor suppressor protein p53, which binds to DNA and activates transcription in response to diverse cellular stresses to induce cell cycle arrest, apoptosis, or DNA repair[1]. In unstressed cells, TP53 is kept inactive by targeted degradation via MDM2, a substrate recognition factor for ubiquitin-dependent proteolysis[100]. Alterations in TP53 are required for oncogenesis as they result in loss of protein function and gain of transforming potential[101]. Germline mutations in TP53 are the underlying cause of Li-Fraumeni syndrome, a complex hereditary cancer predisposition disorder associated with early-onset cancers[102,103].

Biomarker Descriptions (continued)

Alterations and prevalence: TP53 is the most frequently mutated gene in the cancer genome with approximately half of all cancers experiencing TP53 mutations. Ovarian, head and neck, esophageal, and lung squamous cancers have particularly high TP53 mutation rates (60-90%)[5,6,104,105,106,107]. Approximately two-thirds of TP53 mutations are missense mutations and several recurrent missense mutations are common, including substitutions at codons R158, R175, Y220, R248, R273, and R282[5,6]. Invariably, recurrent missense mutations in TP53 inactivate its ability to bind DNA and activate transcription of target genes[108,109,110,111]. Alterations in TP53 are also observed in pediatric cancers[5,6]. Somatic mutations are observed in 53% of non-Hodgkin lymphoma, 24% of soft tissue sarcoma, 19% of glioma, 13% of bone cancer, 9% of B-lymphoblastic leukemia/lymphoma, 4% of embryonal tumors, 3% of Wilms tumor and leukemia, 2% of T-lymphoblastic leukemia/lymphoma, and less than 1% of peripheral nervous system cancers (5 in 1158 cases)[5,6]. Biallelic loss of TP53 is observed in 10% of bone cancer, 2% of Wilms tumor, and less than 1% of B-lymphoblastic leukemia/lymphoma (2 in 731 cases) and leukemia (1 in 250 cases)[5,6].

Potential relevance: The small molecule p53 reactivator, PC14586[112] (2020), received a fast track designation by the FDA for advanced tumors harboring a TP53 Y220C mutation. The FDA has granted fast track designation to the p53 reactivator, eprenetapopt[113], (2019) and breakthrough designation[114] (2020) in combination with azacitidine or azacitidine and venetoclax for acute myeloid leukemia patients (AML) and myelodysplastic syndrome (MDS) harboring a TP53 mutation, respectively. In addition to investigational therapies aimed at restoring wild-type TP53 activity, compounds that induce synthetic lethality are also under clinical evaluation[115,116]. TP53 mutation are a diagnostic marker of SHH-activated, TP53-mutant medulloblastoma[43]. TP53 mutations confer poor prognosis and poor risk in multiple blood cancers including AML, MDS, myeloproliferative neoplasms (MPN), and chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL)[12,22,23,83,84,117]. In mantle cell lymphoma, TP53 mutations are associated with poor prognosis when treated with conventional therapy including hematopoietic cell transplant[118]. Mono- and bi-allelic mutations in TP53 confer unique characteristics in MDS, with multi-hit patients also experiencing associations with complex karyotype, few co-occurring mutations, and high-risk disease presentation as well as predicted death and leukemic transformation independent of the IPSS-R staging system[119].

TERT c.-57A>C

telomerase reverse transcriptase

Background: The TERT gene encodes telomerase reverse transcriptase, a component of the telomerase core enzyme along with the internal telomerase RNA template (TERC)[96]. TERT is repressed in most differentiated cells, resulting in telomerase silencing[96]. In cancer, telomerase reactivation is known to contribute to cellular immortalization[96,97]. Increased TERT expression results in telomerase activation, allowing for unlimited cancer cell proliferation through telomere stabilization[96]. In addition to its role in telomere maintenance, TERT has RNA-dependent RNA polymerase activity, which, when deregulated, can promote oncogenesis by facilitating mitotic progression and cancer cell stemness[96].

Alterations and prevalence: Somatic mutations are observed in 4% of skin cutaneous melanoma and uterine corpus endometrial carcinoma, 3% of kidney renal papillary cell carcinoma, and 2% of pancreatic adenocarcinoma, stomach adenocarcinoma, and sarcoma[5,6]. Additionally, TERT promoter mutations causing upregulation are observed in many cancer types, especially non-aural cutaneous melanoma (80% of cases), and glioblastoma (70% of cases)[97]. Specifically, TERT promoter mutations at C228T and C250T are recurrent and result in de novo binding sites for ETS transcription factors, leading to enhanced TERT transcription[96]. Amplification of TERT is observed in 15% of lung squamous cell carcinoma, 14% of esophageal adenocarcinoma, 13% of adrenocortical carcinoma and lung adenocarcinoma, and 10% of bladder urothelial carcinoma, 9% of ovarian serous cystadenocarcinoma, 6% of cervical squamous cell carcinoma, 5% of liver hepatocellular carcinoma, sarcoma, skin cutaneous melanoma, stomach adenocarcinoma, head and neck squamous cell carcinoma, 4% of uterine carcinosarcoma, 3% of uterine corpus endometrial carcinoma, breast invasive carcinoma, and 2% of diffuse large B-cell lymphoma[5,6]. TERT is overexpressed in over 85% of tumors and is considered a universal tumor associated antigen[98]. Alterations in TERT are rare in pediatric cancers[5,6]. Somatic mutations are observed in less than 1% of B-lymphoblastic leukemia/lymphoma (2 in 252 cases), glioma (2 in 297 cases), bone cancer (1 in 327 cases), and Wilms tumor (1 in 710 cases)[5,6]. TERT amplification is observed in 1-2% of peripheral nervous system cancers (2 in 91 cases), leukemia (2 in 250 cases), and B-lymphoblastic leukemia/lymphoma (5 in 731 cases)[5,6].

Potential relevance: Currently, no therapies are approved for TERT aberrations. TERT promoter mutations are diagnostic of oligodendroglioma IDH-mutant with 1p/19q co-deletion, while the absence of promoter mutations combined with an IDH mutation is characteristic of astrocytoma[44,99]. Due to its immunogenicity and near-universal expression on cancer cells, TERT has been a focus of immunotherapy research, including peptide, dendritic, and DNA vaccines as well as T-cell therapy[98].

ZRSR2 deletion

zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2

Background: The ZRSR2 gene encodes the zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2 protein, a component of the spliceosome. Specifically, ZRSR2 encodes a splicing factor that is involved in the recognition of the 3' intron splice site[55]. ZRSR2 interacts with components of the pre-spliceosome assembly including SRSF2 and U2AF2/U2AF1 heterodimer[55,56]. Mutations in ZRSR2

Biomarker Descriptions (continued)

can lead to deregulated global and alternative mRNA splicing, nuclear-cytoplasm export, and unspliced mRNA degradation while concurrently altering the expression of multiple genes[55,57].

Alterations and prevalence: ZRSR2 alterations including nonsense and frameshift mutations are observed in 5-10% of myelodysplastic syndromes (MDS) and 4% of uterine cancer. ZRSR2 deletions are observed in 4% of diffuse large B-cell lymphoma (DLBCL), 3% of head and neck and esophageal cancers[6,12].

Potential relevance: Mutation of ZRSR2 is associated with poor prognosis in myelodysplastic syndromes as well as poor/adverse risk in acute myeloid leukemia (AML)[12,22,23].

BCOR deletion

BCL6 corepressor

Background: The BCOR gene encodes the B-cell CLL/lymphoma 6 (BCL6) co-repressor protein, which potentiates transcriptional repression by BCL6[7,8]. BCOR also associates with class I and II histone deacetylases (HDACs), suggesting an alternate mechanism for BCOR-mediated transcriptional repression independent of BCL6[8]. Genetic alterations in BCOR result in protein dysfunction, which suggests BCOR functions as a tumor suppressor gene[9,10,11].

Alterations and prevalence: Genetic alterations in BCOR include missense, nonsense, and frameshift mutations that result in loss of function and have been observed in up to 5% of myelodysplastic syndromes (MDS), 5-10% of chronic myelomonocytic leukemia (CMML), and 1-5% of acute myeloid leukemia (AML)[5,12,13,14]. Higher mutational frequencies are reported in some solid tumors, including up to 15% of uterine cancer and 5-10% of colorectal cancer, stomach cancer, cholangiocarcinoma, and melanoma[5,6]. Although less common, BCOR fusions and internal tandem duplications (ITDs) have been reported in certain rare cancer types[15,16,17]. Specifically, BCOR::CCNB3 rearrangements define a particular subset of sarcomas with Ewing sarcoma-like morphology known as BCOR::CCNB3 sarcomas (BCS)[18,19]. Alterations in BCOR are also observed in pediatric cancers[5,6]. Somatic mutations are observed in 13% of soft tissue sarcoma, 4% of glioma, 3% of retinoblastoma, 2% of bone cancer, 1% of B-lymphoblastic leukemia/lymphoma (3 in 252 cases), and less than 1% of embryonal tumors (3 in 332 cases), leukemia (2 in 311 cases), and Wilms tumor (2 in 710 cases)[5,6]. Other alterations have been reported in clear cell carcinoma of the kidney, a rare pediatric renal malignant tumor, with one study reporting the presence of BCOR ITDs in more than 90% of cases[15].

Potential relevance: BCOR rearrangement, including inv(X)(p11.4p11.22) resulting in BCOR::CCNB3 fusion, is diagnostic of sarcoma with BCOR genetic alterations, a subset of undifferentiated round cell sarcomas[20,21]. Additionally, translocation t(x;22)(p11;q13) resulting in ZC3H7B::BCOR fusion is a useful ancillary diagnostic marker of high-grade endometrial stromal sarcoma[20]. Somatic mutation in BCOR is one of the possible molecular abnormality requirements for the diagnosis of myelodysplasia-related AML (AML-MR) and is associated with poor prognosis in AML and MDS[12,13,22,23,24]. In FLT3-ITD negative AML patients under 65 with intermediate cytogenetic prognosis, mutations in BCOR confer inferior overall survival (OS) as well as relapse-free survival (RFS) compared to those without BCOR abnormalities (OS = 13.6% vs. 55%; RFS = 14.3% vs. 44.5%)[14]. Additionally, BCOR ITDs and BCOR::EP300 fusion are molecular alterations of significance in pediatric gliomas[25,26].

USP9X deletion

ubiquitin specific peptidase 9 X-linked

Background: The USP9X gene encodes the ubiquitin specific peptidase 9 X-lined protein[1]. USP9X is a deubiquitinating enzyme (DUB) and a member of the ubiquitin-specific protease (USP) subclass of cysteine proteases[45]. DUBs are responsible for protein deubiquitination, thereby counter-regulating post-transcriptional ubiquitin modification of proteins within the cell[45,46]. USP9X has many substrates and is commonly upregulated in several solid tumor types, supporting an oncogenic role for USP9X[46]. Conversely, in some cancer types, USP9X has been observed to function as a tumor suppressor, suggesting its exact role in cancer may be dependent on its subtrates[46]. In breast cancer, USP9X has been shown to stabilize BRCA1 by inhibiting its ubiquitination, thereby influencing the regulation of homologous recombination and repair[46].

Alterations and prevalence: Somatic mutations are observed in 16% of uterine corpus endometrial carcinoma, 11% of skin cutaneous melanoma, 7% of colorectal adenocarcinoma, 6% of cholangiocarcinoma, 5% of stomach adenocarcinoma, lung squamous cell carcinoma, diffuse large B-cell lymphoma (DLBCL), and head and neck squamous cell carcinoma[5,6]. Biallelic deletions are observed in 4% of esophageal adenocarcinoma, 3% of head and neck squamous cell carcinoma, 2% of mesothelioma, uterine carcinosarcoma, and lung squamous cell carcinoma[5,6].

Potential relevance: Currently, no therapies are approved for USP9X aberrations.

Biomarker Descriptions (continued)

DDX3X deletion

DEAD-box helicase 3, X-linked

Background: The DDX3X gene encodes DEAD-box helicase 3 X-linked, a member of the DEAD-box protein family, which is part of the RNA helicase superfamily II[1,130]. DEAD-box helicases contain twelve conserved motifs including a "DEAD" domain which is characterized by a conserved amino acid sequence of Asp-Glu-Ala-Asp (DEAD)[130,131,132,133]. In DEAD-box proteins, the DEAD domain interacts with β- and γ-phosphates of ATP through Mg2+ and is required for ATP hydrolysis[130]. DDX3X is involved in several processes including the unwinding of double-stranded RNA, splicing of pre-mRNA, RNA export, transcription, and translation[134,135,136,137,138,139,140,141]. Deregulation of DDX3X has been shown to impact cancer progression by modulating proliferation, metastasis, and drug resistance[134].

Alterations and prevalence: Somatic mutations in DDX3X are observed in 9% of skin cutaneous melanoma and uterine corpus endometrial carcinoma, 7% of diffuse large B-cell lymphoma, 4% of cervical squamous cell carcinoma, bladder urothelial carcinoma, and stomach adenocarcinoma, and 2% of lung squamous cell carcinoma and head and neck squamous cell carcinoma[5,6]. Biallelic loss of DDX3X is observed in 4% of esophageal adenocarcinoma, 3% of head and neck squamous cell carcinoma, and 2% of mesothelioma and lung squamous cell carcinoma[5,6].

Potential relevance: Currently, no therapies are approved for DDX3X aberrations.

KDM6A deletion

lysine demethylase 6A

Background: The KDM6A gene encodes the lysine demethylase 6A protein[1]. KDM6A is a histone demethylase that belongs to the KDM6 family of histone H3 lysine demethylases that also includes KDM6B and KDM6C[58]. Methylation of histone lysine and arginine residues functions to regulate transcription and the DNA damage response, specifically in the recruitment of DNA repair proteins and transcriptional repression[32]. KDM6A removes methylation of di- and trimethylated histone 3 lysine 27 (H3K27)[31,58]. KDM6A also interacts with various transcription factors as well as KMT2C, KMT2D, and CBP/p300 chromatin-modifying enzymes, and the SWI/SNF chromatin-remodeling complex to facilitate transcriptional regulation[58]. Mutations in KDM6A lead to activation of the histone methyltransferase, EZH2, resulting in transcriptional repression[58]. KDM6A is believed to function as a tumor suppressor by antagonizing EZH2-mediated transcriptional repression and promoting transcriptional regulation[58,59].

Alterations and prevalence: Somatic mutations in KDM6A are observed in 26% of bladder urothelial carcinoma, 7% of uterine corpus endometrial carcinoma, 5% of skin cutaneous melanoma, lung squamous cell carcinoma, and 4% of esophageal adenocarcinoma, kidney renal papillary cell carcinoma, pancreatic adenocarcinoma, cervical squamous cell carcinoma, and head and neck squamous cell carcinoma[5,6]. Biallelic loss of KDM6A is observed in 8% of esophageal adenocarcinoma, 4% of lung squamous cell carcinoma, 3% of head and neck squamous cell carcinoma, bladder urothelial carcinoma, and pancreatic adenocarcinoma[5,6].

Potential relevance: Currently, no therapies are approved for KDM6A aberrations. Pre-clinical data suggest that KDM6A loss of function or inactivating mutations may respond to EZH2 inhibitors[59].

RBM10 deletion

RNA binding motif protein 10

Background: RBM10 encodes RNA binding motif protein 10, a member of the RNA binding proteins (RBP) family[1,27]. RBM10 regulates RNA splicing and post-transcriptional modification of mRNA[27,28]. RBM10 is suggested to function as a tumor suppressor by promoting apoptosis and inhibiting cellular proliferation through regulation of the MDM2 and p53 feedback loops, as well as influencing BAX expression[27]. RBM10 has been observed to promote transformation and proliferation in lung cancer, supporting an oncogenic role for RBM10[29,30].

Alterations and prevalence: Somatic mutations in RBM10 are observed in 7% of lung adenocarcinoma, 6% of uterine corpus endometrial carcinoma, 4% of bladder urothelial carcinoma, 3% of colorectal adenocarcinoma and skin cutaneous melanoma, and 2% of diffuse large B-cell lymphoma, pancreatic adenocarcinoma, adrenocortical carcinoma, cervical squamous cell carcinoma, esophageal adenocarcinoma, stomach adenocarcinoma, and kidney chromophobe[5,6]. Biallelic loss of RBM10 is observed in 3% of esophageal adenocarcinoma and 2% of head and neck squamous cell carcinoma[5,6]. Amplification of RBM10 is observed in 5% of ovarian serous cystadenocarcinoma, 4% of uterine carcinosarcoma, and 2% of sarcoma, uterine corpus endometrial carcinoma, adrenocortical carcinoma, and diffuse large B-cell lymphoma[5,6].

Potential relevance: Currently, no therapies are approved for RBM10 aberrations.

Biomarker Descriptions (continued)

KDM5C deletion

lysine demethylase 5C

Background: The KDM5C gene encodes the lysine demethylase 5C protein, a histone demethylase, also known as JARID1C[1,31]. Methylation of histone lysine and arginine residues functions to regulate transcription and DNA damage response[32]. KDM5C removes methylation of di- and trimethylated histone H3 lysine 4 (H3K4) and is involved in the repression of transcription in response to DNA damage[31,32]. KDM5C alterations result in aberrant H3K4 trimethylation at active replication origins which can lead to stalled DNA replication[33].

Alterations and prevalence: Somatic mutations in KDM5C are observed in 9% of uterine corpus endometrial carcinoma, 5% of kidney renal clear cell carcinoma, stomach adenocarcinoma, skin cutaneous melanoma, 4% of lung adenocarcinoma and uterine carcinosarcoma[5,6]. Biallelic loss of KDM5C is observed in 3% of esophageal adenocarcinoma and 2% of head and neck squamous cell carcinoma[5,6].

Potential relevance: Currently, no therapies are approved for KDM5C aberrations.

SMC1A deletion

structural maintenance of chromosomes 1A

Background: SMC1A encodes the structural maintenance of chromosomes 1A and belongs to structural maintenance of chromosomes (SMCs) family, which consists of SMC1A, SMC1B, SMC2, SMC3, SMC4, SMC5, and SMC6[1,66,67]. As a part of the cohesion-core complex, SMC1A plays a crucial role in chromosome segregation during mitosis and meiosis[66,68]. SMC1A also plays a role in cell cycle regulation, DNA damage repair, gene transcription regulation, and genomic organization[66]. SMC1A aberrations, including overexpression, have been observed in several cancer types and have been proposed to promote tumor formation and epithelial to mesenchymal transition[67,69].

Alterations and prevalence: Somatic mutations in SMC1A are observed in 11% of uterine corpus endometrial carcinoma, 5% of skin cutaneous melanoma and acute myeloid leukemia, 4% of colorectal adenocarcinoma and bladder urothelial carcinoma, 3% cervical squamous cell carcinoma and glioblastoma multiforme, 2% diffuse large B-Cell lymphoma, adrenocortical carcinoma, stomach adenocarcinoma, uterine carcinosarcoma, ovarian serous cystadenocarcinoma and lung adenocarcinoma[5,6]. Amplification of SMC1A is found in 4% of diffuse large B-Cell lymphoma, 3% of sarcoma, and 2% of ovarian serous cystadenocarcinoma, adrenocortical carcinoma, and uterine carcinosarcoma[5,6]. Biallelic loss of SMC1A is found in 3% of esophageal adenocarcinoma and 2% of head and neck squamous cell carcinoma[5,6].

Potential relevance: Currently, no therapies are approved for SMC1A aberrations.

AMER1 deletion

APC membrane recruitment protein 1

Background: The AMER1 gene encodes APC membrane recruitment protein 1[1]. AMER1 works in complex with CTNNB1, APC, AXIN1, and AXIN2 to regulate the WNT pathway[1,90]. The WNT signaling pathway is responsible for regulating several key components during embryogenesis and has been observed to be involved in tumorigenesis[91,92]. Consequently, the WNT signaling pathway is a target for therapeutic response in various cancer types[92]. The AMER1 gene is located on the X chromosome and is commonly inactivated in Wilms tumor, a pediatric kidney cancer[93]. AMER1 has also been observed to influence cell proliferation, tumorigenesis, migration, invasion, and cell cycle arrest[90].

Alterations and prevalence: Somatic mutations of AMER1 are observed in 13% of colorectal adenocarcinoma,10% of uterine corpus endometrial carcinoma, 8% of skin cutaneous melanoma, 7% of lung adenocarcinoma, 4% of stomach adenocarcinoma, and uterine carcinosarcoma, 3% of lung squamous cell carcinoma, cervical squamous cell carcinoma, bladder urothelial carcinoma, and 2% of diffuse large B-cell lymphoma, liver hepatocellular carcinoma, head and neck squamous cell carcinoma, and breast invasive carcinoma[5,6]. Biallelic deletion of AMER1 is observed in 2% of esophageal adenocarcinoma, diffuse large b-cell lymphoma, uterine carcinosarcoma, lung squamous cell carcinoma, and pancreatic adenocarcinoma, and 1% of stomach adenocarcinoma, sarcoma, liver hepatocellular carcinoma, colorectal adenocarcinoma, head and neck squamous cell carcinoma, uterine corpus endometrial carcinoma, and ovarian serous cystadenocarcinoma[5,6].

Potential relevance: Currently, no therapies are approved for AMER1 aberrations.

Biomarker Descriptions (continued)

ZMYM3 deletion

zinc finger MYM-type containing 3

Background: The ZMYM3 gene encodes the zinc finger MYM-type containing 3 protein[1]. While the function is not fully understood, ZMYM3 is capable of binding histones and DNA, and may facilitate the repair of double-strand breaks (DSBs)[94].

Alterations and prevalence: Somatic mutations in ZMYM3 are observed in 12% of uterine corpus endometrial carcinoma, 5% of skin cutaneous melanoma, 4% of colorectal adenocarcinoma, 3% of lung adenocarcinoma, lung squamous cell carcinoma, cervical squamous cell carcinoma, esophageal adenocarcinoma, and bladder urothelial carcinoma[5,6]. In prostate cancer, ZMYM3 mutations have been observed to be enriched in African American men compared to white men with one study demonstrating occurrence in 11.7% vs. 2.7% of patients, respectively[95]. Biallelic deletion of ZMYM3 is observed in 3% of cholangiocarcinoma and 2% of sarcoma and kidney chromophobe[5,6].

Potential relevance: Currently, no therapies are approved for ZMYM3 aberrations.

STAG2 deletion

stromal antigen 2

Background: The STAG2 gene encodes the stromal antigen 2 protein, one of the core proteins in the cohesin complex, which regulates the separation of sister chromatids during cell division[47,48]. Components of the cohesion complex include SMC1A, SMC3, and RAD21, which bind to STAG1/STAG2 paralogs[49,50]. Inactivating mutations in STAG2 contribute to X-linked neurodevelopmental disorders, aneuploidy, and chromosomal instability in cancer[49,51].

Alterations and prevalence: Somatic mutations in STAG2 include nonsense, frameshift, splice site variants[12]. Somatic mutations in STAG2 are observed in various solid tumors including 14% of bladder cancer, 10% of uterine cancer, 3% of stomach cancer, and 4% of lung adenocarcinoma[6]. In addition, mutations in STAG2 are observed in 5-10% of myelodysplastic syndrome(MDS), 3% of acute myeloid leukemia, and 2% of diffuse large B-cell lymphoma[6,12].

Potential relevance: Mutations in STAG2 are associated with poor prognosis and adverse risk in MDS and Acute Myeloid Leukemia[12,22,23]. Truncating mutations in STAG2 lead to a loss of function in bladder cancer and are often identified as an early event associated with low grade and stage tumors[52].

PHF6 deletion

PHD finger protein 6

Background: The PHF6 gene encodes the plant homeodomain (PHD) finger protein 6 which contains four nuclear localization signals and two imperfect PHD zinc finger domains. PHF6 is a tumor suppressor that interacts with the nucleosome remodeling deacetylase (NuRD) complex, which regulates nucleosome positioning and transcription of genes involved in development and cell-cycle progression[60,61].

Alterations and prevalence: The majority of PHF6 aberrations are nonsense, frameshift (70%), or missense (30%) mutations, which result in complete loss of protein expression[60,62,63,64]. Truncating or missense mutations in PHF6 are observed in 38% of adult and 16% of pediatric T-cell acute lymphoblastic leukemia (T-ALL), 20-25% of mixed phenotype acute leukemias (MPAL), and 3% of AML, and 2.6% of hepatocellular carcinoma (HCC)[62,64]. Missense mutations recurrently involve codon C215 and the second zinc finger domain of PHF6[62]. PHF6 mutations are frequently observed in hematologic malignancies from male patients[60,62].

Potential relevance: Somatic mutations in PHF6 are associated with reduced overall survival in AML patients treated with high-dose induction chemotherapy[65].

Genes Assayed

Genes Assayed for the Detection of DNA Sequence Variants

ABL1, ABL2, ACVR1, AKT1, AKT2, AKT3, ALK, AR, ARAF, ATP1A1, AURKA, AURKB, AURKC, AXL, BCL2, BCL2L12, BCL6, BCR, BMP5, BRAF, BTK, CACNA1D, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CD79B, CDK4, CDK6, CHD4, CSF1R, CTNNB1, CUL1, CYSLTR2,

Genes Assayed (continued)

Genes Assayed for the Detection of DNA Sequence Variants (continued)

DDR2, DGCR8, DROSHA, E2F1, EGFR, EIF1AX, EPAS1, ERBB2, ERBB3, ERBB4, ESR1, EZH2, FAM135B, FGF7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FOXL2, FOXO1, GATA2, GLI1, GNA11, GNAQ, GNAS, HIF1A, HRAS, IDH1, IDH2, IKBKB, IL6ST, IL7R, IRF4, IRS4, KCNJ5, KDR, KIT, KLF4, KLF5, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAPK1, MAX, MDM4, MECOM, MED12, MEF2B, MET, MITF, MPL, MTOR, MYC, MYCN, MYD88, MYOD1, NFE2L2, NRAS, NSD2, NT5C2, NTRK1, NTRK2, NTRK3, NUP93, PAX5, PCBP1, PDGFRA, PDGFRB, PIK3C2B, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R2, PIM1, PLCG1, PPP2R1A, PPP6C, PRKACA, PTPN11, PTPRD, PXDNL, RAC1, RAF1, RARA, RET, RGS7, RHEB, RHOA, RICTOR, RIT1, ROS1, RPL10, SETBP1, SF3B1, SIX1, SIX2, SLCO1B3, SMC1A, SMO, SNCAIP, SOS1, SOX2, SPOP, SRC, SRSF2, STAT3, STAT5B, STAT6, TAF1, TERT, TGFBR1, TOP1, TOP2A, TPMT, TRRAP, TSHR, U2AF1, USP8, WAS, XPO1, ZNF217, ZNF429

Genes Assayed for the Detection of Copy Number Variations

ABCB1, ABL1, ABL2, ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AKT1, AKT2, AKT3, ALK, AMER1, APC, AR, ARAF, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AURKA, AURKC, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BCL2, BCL2L12, BCL6, BCOR, BLM, BMPR2, BRAF, BRCA1, BRCA2, BRIP1, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHD4, CHEK1, CHEK2, CIC, CREBBP, CSMD3, CTCF, CTLA4, CTNND2, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, DAXX, DDR1, DDR2, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, EGFR, EIF1AX, ELF3, EMSY, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERBB2, ERBB3, ERBB4, ERCC2, ERCC4, ERRFI1, ESR1, ETV6, EZH2, FAM135B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAT1, FBXW7, FGF19, FGF23, FGF3, FGF4, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FUBP1, FYN, GATA2, GATA3, GLI3, GNA13, GNAS, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, IDH2, IGF1R, IKBKB, IL7R, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KDR, KEAP1, KIT, KLF5, KMT2A, KMT2B, KMT2C, KMT2D, KRAS, LARP4B, LATS1, LATS2, MAGOH, MAP2K1, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK1, MAPK8, MAX, MCL1, MDM2, MDM4, MECOM, MEF2B, MEN1, MET, MGA, MITF, MLH1, MLH3, MPL, MRE11, MSH2, MSH3, MSH6, MTAP, MTOR, MUTYH, MYC, MYCL, MYCN, MYD88, NBN, NCOR1, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NRAS, NTRK1, NTRK3, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PCBP1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDIA3, PGD, PHF6, PIK3C2B, PIK3CA, PIK3CB, PIK3R1, PIK3R2, PIM1, PLCG1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PRDM9, PRKACA, PRKAR1A, PTCH1, PTEN, PTPN11, PTPRT, PXDNL, RAC1, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RASA1, RASA2, RB1, RBM10, RECQL4, RET, RHEB, RICTOR, RIT1, RNASEH2A, RNASEH2B, RNF43, ROS1, RPA1, RPS6KB1, RPTOR, RUNX1, SDHA, SDHB, SDHD, SETBP1, SETD2, SF3B1, SLCO1B3, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SMC1A, SMO, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STAT6, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TERT, TET2, TGFBR2, TNFAIP3, TNFRSF14, TOP1, TP53, TP63, TPMT, TPP2, TSC1, TSC2, U2AF1, USP8, USP9X, VHL, WT1, XPO1, XRCC2, XRCC3, YAP1, YES1, ZFHX3, ZMYM3, ZNF217, ZNF429, ZRSR2

Genes Assayed for the Detection of Fusions

AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT

Genes Assayed with Full Exon Coverage

ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AMER1, APC, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AXIN1, AXIN2, B2M, BAP1, BARD1, BCOR, BLM, BMPR2, BRCA1, BRCA2, BRIP1, CALR, CASP8, CBFB, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHEK1, CHEK2, CIC, CIITA, CREBBP, CSMD3, CTCF, CTLA4, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, CYP2D6, DAXX, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, ELF3, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERCC2, ERCC4, ERCC5, ERRFI1, ETV6, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FAT1, FBXW7, FUBP1, GATA3, GNA13, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, ID3, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KEAP1, KLHL13, KMT2A, KMT2B, KMT2C, KMT2D, LARP4B, LATS1, LATS2, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK8, MEN1, MGA, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MTAP, MTUS2, MUTYH, NBN, NCOR1, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PDCD1, PDCD1LG2, PDIA3, PGD, PHF6, PIK3R1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R2A, PRDM1, PRDM9, PRKAR1A, PSMB10, PSMB8, PSMB9, PTCH1, PTEN, PTPRT, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RASA1, RASA2, RB1, RBM10, RECQL4, RNASEH2A, RNASEH2B, RNASEH2C, RNF43, RPA1, RPL22, RPL5, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETD2, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SOCS1, SOX9, SPEN, STAG2, STAT1, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TET2, TGFBR2, TMEM132D, TNFAIP3, TNFRSF14, TP53, TP63, TPP2, TSC1, TSC2, UGT1A1, USP9X, VHL, WT1, XRCC2, XRCC3, ZBTB20, ZFHX3, ZMYM3, ZRSR2

Relevant Therapy Summary

● In this cancer type   ○ In other cancer type   ◑ In this cancer type and other cancer types   ✖ No evidence

ATRX deletion

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
pamiparib, tislelizumab	✖	✖	✖	✖	● (II)

BARD1 deletion

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
pamiparib, tislelizumab	✖	✖	✖	✖	● (II)

CHEK2 deletion

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
pamiparib, tislelizumab	✖	✖	✖	✖	● (II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

HRR Details

Gene/Genomic Alteration	Finding
LOH percentage	*10.98%*
BRCA1	*SNV, S1514C, AF:0.22*
BARD1	*CNV, CN:1.0*
BARD1	*LOH, 2q35(215593375-215674382)x1*
CHEK2	*CNV, CN:1.0*
CHEK2	*LOH, 22q12.1(29083868-29130729)x1*

Homologous recombination repair (HRR) genes were defined from published evidence in relevant therapies, clinical guidelines, as well as clinical trials, and include - BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L.

Thermo Fisher Scientific's Ion Torrent Oncomine Reporter software was used in generation of this report. Software was developed and designed internally by Thermo Fisher Scientific. The analysis was based on Oncomine Reporter (6.1.1 data version 2025.06(006)). The data presented here are from a curated knowledge base of publicly available information, but may not be exhaustive. FDA information was sourced from www.fda.gov and is current as of 2025-05-14. NCCN information was sourced from www.nccn.org and is current as of 2025-05-01. EMA information was sourced from www.ema.europa.eu and is current as of 2025-05-14. ESMO information was sourced from www.esmo.org and is current as of 2025-05-01. Clinical Trials information is current as of 2025-05-01. For the most up-to-date information regarding a particular trial, search www.clinicaltrials.gov by NCT ID or search local clinical trials authority website by local identifier listed in 'Other identifiers.' Variants are reported according to HGVS nomenclature and classified following AMP/ASCO/CAP guidelines (Li et al. 2017). Based on the data sources selected, variants, therapies, and trials listed in this report are listed in order of potential clinical significance but not for predicted efficacy of the therapies.

References

1. O'Leary et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45. PMID: 26553804

2. Sarikas et al. The cullin protein family. Genome Biol. 2011;12(4):220. PMID: 21554755

3. Sang et al. The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications. Oncotarget. 2015 Dec 15;6(40):42590-602. PMID: 26460955

4. Cheng et al. The emerging role for Cullin 4 family of E3 ligases in tumorigenesis. Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):138-159. PMID: 30602127

5. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013 Oct;45(10):1113-20. PMID: 24071849

6. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401-4. PMID: 22588877

7. Gearhart et al. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets. Mol. Cell. Biol. 2006 Sep;26(18):6880-9. PMID: 16943429

8. Huynh et al. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev. 2000 Jul 15;14(14):1810-23. PMID: 10898795

9. Kelly et al. Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. Nat Commun. 2019 Mar 22;10(1):1347. PMID: 30902969

10. Cao et al. BCOR regulates myeloid cell proliferation and differentiation. Leukemia. 2016 May;30(5):1155-65. PMID: 26847029

11. Yamamoto et al. Clarifying the impact of polycomb complex component disruption in human cancers. Mol. Cancer Res. 2014 Apr;12(4):479-84. PMID: 24515802

12. NCCN Guidelines® - NCCN-Myelodysplastic Syndromes [Version 2.2025]

13. Damm et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013 Oct 31;122(18):3169-77. PMID: 24047651

14. Terada et al. Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis. Genes Chromosomes Cancer. 2018 Aug;57(8):401-408. PMID: 29663558

15. Wong et al. Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion. Histopathology. 2018 Jan;72(2):320-329. PMID: 28833375

16. Cramer et al. Successful Treatment of Recurrent Primitive Myxoid Mesenchymal Tumor of Infancy With BCOR Internal Tandem Duplication. J Natl Compr Canc Netw. 2017 Jul;15(7):868-871. PMID: 28687574

17. Peters et al. BCOR-CCNB3 fusions are frequent in undifferentiated sarcomas of male children. Mod. Pathol. 2015 Apr;28(4):575-86. PMID: 25360585

18. Puls et al. BCOR-CCNB3 (Ewing-like) sarcoma: a clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma. Am. J. Surg. Pathol. 2014 Oct;38(10):1307-18. PMID: 24805859

19. Kao et al. BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am. J. Surg. Pathol. 2018 May;42(5):604-615. PMID: 29300189

20. NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 5.2024]

21. NCCN Guidelines® - NCCN-Bone Cancer [Version 2.2025]

22. NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 2.2025]

23. Döhner et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-1377. PMID: 35797463

24. Khoury et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703-1719. PMID: 35732831

25. Torre et al. Recurrent EP300-BCOR Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features. J Neuropathol Exp Neurol. 2019 Apr 1;78(4):305-314. PMID: 30816933

26. Wang et al. Clinical, pathological, and molecular features of central nervous system tumors with BCOR internal tandem duplication. Pathol Res Pract. 2024 Jul;259:155367. PMID: 38797130

27. Cao et al. RBM10 Regulates Tumor Apoptosis, Proliferation, and Metastasis. Front Oncol. 2021;11:603932. PMID: 33718153

28. Zhang et al. RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H. EBioMedicine. 2020 Nov;61:103067. PMID: 33130397

29. Sun et al. Functional role of RBM10 in lung adenocarcinoma proliferation. Int J Oncol. 2019 Feb;54(2):467-478. PMID: 30483773

30. Loiselle et al. RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5. PLoS One. 2017;12(6):e0180258. PMID: 28662214

References (continued)

31. Iwase et al. The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell. 2007 Mar 23;128(6):1077-88. PMID: 17320160

32. Gong et al. Histone methylation and the DNA damage response. Mutat Res. 2017 Sep 23;780:37-47. PMID: 31395347

33. Rondinelli et al. H3K4me3 demethylation by the histone demethylase KDM5C/JARID1C promotes DNA replication origin firing. Nucleic Acids Res. 2015 Mar 11;43(5):2560-74. PMID: 25712104

34. Ryan et al. Snf2-family proteins: chromatin remodellers for any occasion. Curr Opin Chem Biol. 2011 Oct;15(5):649-56. PMID: 21862382

35. Heyer et al. Rad54: the Swiss Army knife of homologous recombination?. Nucleic Acids Res. 2006;34(15):4115-25. PMID: 16935872

36. Matsuda et al. Mutations in the RAD54 recombination gene in primary cancers. Oncogene. 1999 Jun 3;18(22):3427-30. PMID: 10362365

37. Abedalthagafi et al. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Mod. Pathol. 2013 Nov;26(11):1425-32. PMID: 23765250

38. Clynes et al. ATRX dysfunction induces replication defects in primary mouse cells. PLoS ONE. 2014;9(3):e92915. PMID: 24651726

39. Tang et al. A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein. J. Biol. Chem. 2004 May 7;279(19):20369-77. PMID: 14990586

40. Xue et al. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc. Natl. Acad. Sci. U.S.A. 2003 Sep 16;100(19):10635-40. PMID: 12953102

41. Pisapia. The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas. Arch. Pathol. Lab. Med. 2017 Dec;141(12):1633-1645. PMID: 29189064

42. Jiao et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012 Jul;3(7):709-22. PMID: 22869205

43. Louis et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. PMID: 34185076

44. NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 5.2024]

45. Dufner et al. Ubiquitin-specific protease 8 (USP8/UBPy): a prototypic multidomain deubiquitinating enzyme with pleiotropic functions. Biochem Soc Trans. 2019 Dec 20;47(6):1867-1879. PMID: 31845722

46. Lu et al. USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells. Cancer Med. 2019 Nov;8(15):6730-6740. PMID: 31512408

47. Mehta et al. Cohesin: functions beyond sister chromatid cohesion. FEBS Lett. 2013 Aug 2;587(15):2299-312. PMID: 23831059

48. Aquila et al. The role of STAG2 in bladder cancer. Pharmacol. Res. 2018 May;131:143-149. PMID: 29501732

49. Mullegama et al. De novo loss-of-function variants in STAG2 are associated with developmental delay, microcephaly, and congenital anomalies. Am. J. Med. Genet. A. 2017 May;173(5):1319-1327. PMID: 28296084

50. van et al. Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. Elife. 2017 Jul 10;6. PMID: 28691904

51. Solomon et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 2011 Aug 19;333(6045):1039-43. PMID: 21852505

52. Solomon et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat. Genet. 2013 Dec;45(12):1428-30. PMID: 24121789

53. D'Alessandro et al. BRCA2 controls DNA:RNA hybrid level at DSBs by mediating RNase H2 recruitment. Nat Commun. 2018 Dec 18;9(1):5376. PMID: 30560944

54. Aden et al. Epithelial RNase H2 Maintains Genome Integrity and Prevents Intestinal Tumorigenesis in Mice. Gastroenterology. 2019 Jan;156(1):145-159.e19. PMID: 30273559

55. Madan et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. . Nat Commun. 2015 Jan 14;6:6042. doi: 10.1038/ncomms7042. PMID: 25586593

56. Tronchère et al. A protein related to splicing factor U2AF35 that interacts with U2AF65 and SR proteins in splicing of pre-mRNA. Nature. 1997 Jul 24;388(6640):397-400. PMID: 9237760

57. Chesnais et al. Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia. Oncotarget. 2012 Nov;3(11):1284-93. PMID: 23327988

58. Tran et al. Lysine Demethylase KDM6A in Differentiation, Development, and Cancer. Mol Cell Biol. 2020 Sep 28;40(20). PMID: 32817139

References (continued)

59. Ler et al. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci Transl Med. 2017 Feb 22;9(378). PMID: 28228601

60. Wendorff et al. Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. Cancer Discov. 2019 Mar;9(3):436-451. PMID: 30567843

61. Lower et al. Mutations in PHF6 are associated with Börjeson-Forssman-Lehmann syndrome. Nat. Genet. 2002 Dec;32(4):661-5. PMID: 12415272

62. Van et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat. Genet. 2010 Apr;42(4):338-42. PMID: 20228800

63. Van et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011 Jan;25(1):130-4. PMID: 21030981

64. Yoo et al. Somatic mutation of PHF6 gene in T-cell acute lymphoblatic leukemia, acute myelogenous leukemia and hepatocellular carcinoma. Acta Oncol. 2012 Jan;51(1):107-11. PMID: 21736506

65. Patel et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 2012 Mar 22;366(12):1079-89. PMID: 22417203

66. Musio. The multiple facets of the SMC1A gene. Gene. 2020 Jun 15;743:144612. PMID: 32222533

67. Nie et al. Clinical Significance and Integrative Analysis of the SMC Family in Hepatocellular Carcinoma. Front Med (Lausanne). 2021;8:727965. PMID: 34527684

68. Yatskevich et al. Organization of Chromosomal DNA by SMC Complexes. Annu Rev Genet. 2019 Dec 3;53:445-482. PMID: 31577909

69. Yadav et al. SMC1A is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties. Mol Carcinog. 2019 Jan;58(1):113-125. PMID: 30242889

70. Li et al. Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. J Hematol Oncol. 2021 Apr 6;14(1):56. PMID: 33823889

71. Huang et al. Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation. Oncotarget. 2017 Sep 8;8(38):63110-63120. PMID: 28968975

72. Krivtsov et al. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer. 2007 Nov;7(11):823-33. PMID: 17957188

73. Ayton et al. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001 Sep 10;20(40):5695-707. PMID: 11607819

74. DiMartino et al. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood. 2002 May 15;99(10):3780-5. PMID: 11986236

75. Biswas et al. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc. Natl. Acad. Sci. U.S.A. 2011 Sep 20;108(38):15751-6. PMID: 21896721

76. Schoch et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003 Oct 1;102(7):2395-402. PMID: 12805060

77. Rao et al. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat. Rev. Cancer. 2015 Jun;15(6):334-46. PMID: 25998713

78. Biondi et al. Biological and therapeutic aspects of infant leukemia. Blood. 2000 Jul 1;96(1):24-33. PMID: 10891426

79. Pui et al. Biology and treatment of infant leukemias. Leukemia. 1995 May;9(5):762-9. PMID: 7769837

80. Krauter et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J. Clin. Oncol. 2009 Jun 20;27(18):3000-6. PMID: 19380453

81. Balgobind et al. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia. 2011 Aug;25(8):1239-48. PMID: 21566656

82. Tamai et al. 11q23/MLL acute leukemia : update of clinical aspects. J Clin Exp Hematop. 2010;50(2):91-8. PMID: 21123966

83. NCCN Guidelines® - NCCN-Myeloproliferative Neoplasms [Version 1.2025]

84. NCCN Guidelines® - NCCN-Acute Lymphoblastic Leukemia [Version 3.2024]

85. NCCN Guidelines® - NCCN-Pediatric Acute Lymphoblastic Leukemia [Version 3.2025]

86. Górecki et al. Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia. Biomedicines. 2023 Mar 8;11(3). PMID: 36979800

87. Alaggio et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul;36(7):1720-1748. PMID: 35732829

References (continued)

88. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf

89. https://www.onclive.com/view/fda-grants-fast-track-designation-to-dsp-5336-in-kmt2a-nmp1-aml

90. Liu et al. Aging (Albany NY). 2020 May 4;12(9):8372-8396. PMID: 32365332

91. Komiya et al. Wnt signal transduction pathways. Organogenesis. 2008 Apr;4(2):68-75. PMID: 19279717

92. Zhang et al. J Hematol Oncol. 2020 Dec 4;13(1):165. PMID: 33276800

93. Rivera et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007 Feb 2;315(5812):642-5. PMID: 17204608

94. Leung et al. ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair. Genes Dev. 2017 Feb 1;31(3):260-274. PMID: 28242625

95. Liu et al. Distinct Genomic Alterations in Prostate Tumors Derived from African American Men. Mol Cancer Res. 2020 Dec;18(12):1815-1824. PMID: 33115829

96. Yuan et al. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019 Aug;38(34):6172-6183. PMID: 31285550

97. Colebatch et al. TERT gene: its function and dysregulation in cancer. J Clin Pathol. 2019 Apr;72(4):281-284. PMID: 30696697

98. Mizukoshi et al. Telomerase-Targeted Cancer Immunotherapy. Int J Mol Sci. 2019 Apr 12;20(8). PMID: 31013796

99. Arita et al. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathol Commun. 2020 Nov 23;8(1):201. PMID: 33228806

100. Nag et al. The MDM2-p53 pathway revisited. J Biomed Res. 2013 Jul;27(4):254-71. PMID: 23885265

101. Muller et al. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014 Mar 17;25(3):304-17. PMID: 24651012

102. Olivier et al. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008. PMID: 20182602

103. Guha et al. Inherited TP53 Mutations and the Li-Fraumeni Syndrome. Cold Spring Harb Perspect Med. 2017 Apr 3;7(4). PMID: 28270529

104. Peter et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27;489(7417):519-25. PMID: 22960745

105. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29;517(7536):576-82. PMID: 25631445

106. Campbell et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 2016 Jun;48(6):607-16. PMID: 27158780

107. Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017 Jan 12;541(7636):169-175. doi: 10.1038/nature20805. Epub 2017 Jan 4. PMID: 28052061

108. Olivier et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 2002 Jun;19(6):607-14. PMID: 12007217

109. Rivlin et al. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011 Apr;2(4):466-74. PMID: 21779514

110. Petitjean et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007 Apr 2;26(15):2157-65. PMID: 17401424

111. Soussi et al. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. Hum. Mutat. 2014 Jun;35(6):766-78. PMID: 24729566

112. https://www.globenewswire.com/news-release/2020/10/13/2107498/0/en/PMV-Pharma-Granted-FDA-Fast-Track-Designation-of-PC14586-for-the-Treatment-of-Advanced-Cancer-Patients-that-have-Tumors-with-a-p53-Y220C-Mutation.html

113. https://ir.aprea.com//news-releases/news-release-details/aprea-therapeutics-receives-fda-fast-track-designation

114. http://vp280.alertir.com/en/pressreleases/karolinska-development%27s-portfolio-company-aprea-therapeutics-receives-fda-breakthrough-therapy-designation-1769167

115. Parrales et al. Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol. 2015 Dec 21;5:288. doi: 10.3389/fonc.2015.00288. eCollection 2015. PMID: 26732534

116. Zhao et al. Molecularly targeted therapies for p53-mutant cancers. Cell. Mol. Life Sci. 2017 Nov;74(22):4171-4187. PMID: 28643165

117. NCCN Guidelines® - NCCN-Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Version 3.2025]

References (continued)

118. NCCN Guidelines® - NCCN-B-Cell Lymphomas [Version 2.2025]

119. Bernard et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat. Med. 2020 Aug 3. PMID: 32747829

120. Morris et al. BRCA1 : BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum. Mol. Genet. 2004 Apr 15;13(8):807-17. PMID: 14976165

121. Baer et al. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 2002 Feb;12(1):86-91. PMID: 11790560

122. Zhao et al. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature. 2017 Oct 19;550(7676):360-365. PMID: 28976962

123. Cimmino et al. Dualistic Role of BARD1 in Cancer. Genes (Basel). 2017 Dec 8;8(12). PMID: 29292755

124. De et al. BRCAness: a deeper insight into basal-like breast tumors. Ann. Oncol. 2013 Nov;24 Suppl 8:viii13-viii21. PMID: 24131964

125. Prakash et al. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015 Apr 1;7(4):a016600. PMID: 25833843

126. Irminger-Finger et al. Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. Mol. Cell. 2001 Dec;8(6):1255-66. PMID: 11779501

127. Thai et al. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum. Mol. Genet. 1998 Feb;7(2):195-202. PMID: 9425226

128. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf

129. https://www.senhwabio.com//en/news/20220125

130. Rocak et al. DEAD-box proteins: the driving forces behind RNA metabolism. Nat Rev Mol Cell Biol. 2004 Mar;5(3):232-41. PMID: 14991003

131. Fuller-Pace. The DEAD box proteins DDX5 (p68) and DDX17 (p72): multi-tasking transcriptional regulators. Biochim Biophys Acta. 2013 Aug;1829(8):756-63. PMID: 23523990

132. Ali. DEAD-box RNA helicases: The driving forces behind RNA metabolism at the crossroad of viral replication and antiviral innate immunity. Virus Res. 2021 Apr 15;296:198352. PMID: 33640359

133. Linder et al. Looking back on the birth of DEAD-box RNA helicases. Biochim Biophys Acta. 2013 Aug;1829(8):750-5. PMID: 23542735

134. Lin. DDX3X Multifunctionally Modulates Tumor Progression and Serves as a Prognostic Indicator to Predict Cancer Outcomes. Int J Mol Sci. 2019 Dec 31;21(1). PMID: 31906196

135. Song et al. The mechanism of RNA duplex recognition and unwinding by DEAD-box helicase DDX3X. Nat Commun. 2019 Jul 12;10(1):3085. PMID: 31300642

136. Zhou et al. Comprehensive proteomic analysis of the human spliceosome. Nature. 2002 Sep 12;419(6903):182-5. PMID: 12226669

137. Yedavalli et al. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell. 2004 Oct 29;119(3):381-92. PMID: 15507209

138. Chao et al. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer Res. 2006 Jul 1;66(13):6579-88. PMID: 16818630

139. Chuang et al. Requirement of the DEAD-Box protein ded1p for messenger RNA translation. Science. 1997 Mar 7;275(5305):1468-71. PMID: 9045610

140. Shih et al. Candidate tumor suppressor DDX3 RNA helicase specifically represses cap-dependent translation by acting as an eIF4E inhibitory protein. Oncogene. 2008 Jan 24;27(5):700-14. PMID: 17667941

141. Lee et al. Human DDX3 functions in translation and interacts with the translation initiation factor eIF3. Nucleic Acids Res. 2008 Aug;36(14):4708-18. PMID: 18628297

142. Lander et al. Initial sequencing and analysis of the human genome. Nature. 2001 Feb 15;409(6822):860-921. PMID: 11237011

143. Baudrin et al. Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer. Front Oncol. 2018 Dec 12;8:621. doi: 10.3389/fonc.2018.00621. eCollection 2018. PMID: 30631754

144. Nojadeh et al. Microsatellite instability in colorectal cancer. EXCLI J. 2018;17:159-168. PMID: 29743854

145. Saeed et al. Microsatellites in Pursuit of Microbial Genome Evolution. Front Microbiol. 2016 Jan 5;6:1462. doi: 10.3389/fmicb.2015.01462. eCollection 2015. PMID: 26779133

References (continued)

146. Boland et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998 Nov 15;58(22):5248-57. PMID: 9823339

147. Halford et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res. 2002 Jan 1;62(1):53-7. PMID: 11782358

148. Imai et al. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008 Apr;29(4):673-80. PMID: 17942460

149. NCCN Guidelines® - NCCN-Colon Cancer [Version 3.2025]

150. Pawlik et al. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis. Markers. 2004;20(4-5):199-206. PMID: 15528785

151. Lee et al. Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer. Medicine (Baltimore). 2015 Dec;94(50):e2260. PMID: 26683947

152. Latham et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J. Clin. Oncol. 2019 Feb 1;37(4):286-295. PMID: 30376427

153. Cortes-Ciriano et al. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017 Jun 6;8:15180. doi: 10.1038/ncomms15180. PMID: 28585546

154. Bonneville et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2017;2017. PMID: 29850653

155. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf

156. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf

157. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s009lbl.pdf

158. NCCN Guidelines® - NCCN-Rectal Cancer [Version 2.2025]

159. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf

160. Ribic et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003 Jul 17;349(3):247-57. PMID: 12867608

161. Klingbiel et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann. Oncol. 2015 Jan;26(1):126-32. PMID: 25361982

162. Hermel et al. The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer. J Pers Med. 2019 Jan 16;9(1). PMID: 30654522

163. Ciardiello et al. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treat. Rev. 2019 Jun;76:22-32. PMID: 31079031

164. Matsuoka et al. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 1998 Dec 4;282(5395):1893-7. PMID: 9836640

165. Cai et al. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. Mol. Cell. 2009 Sep 24;35(6):818-29. PMID: 19782031

166. Zhang et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol. Cell. Biol. 2004 Jan;24(2):708-18. PMID: 14701743

167. Huang et al. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol. Cancer Ther. 2008 Jun;7(6):1440-9. PMID: 18566216

168. Apostolou et al. Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer (Dove Med Press). 2017;9:331-335. PMID: 28553140

169. Nevanlinna et al. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006 Sep 25;25(43):5912-9. PMID: 16998506

170. Näslund-Koch et al. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study. J. Clin. Oncol. 2016 Apr 10;34(11):1208-16. PMID: 26884562

171. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217439s000lbl.pdf